| Dr Demetria M Francis, MD | |
|
3650 Steve Reynolds Blvd, Kaiser Permanente Gwinnett Medical Center, Duluth, GA 30096-4506 | |
| (770) 931-6220 | |
| Not Available |
| Full Name | Dr Demetria M Francis |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 3650 Steve Reynolds Blvd, Duluth, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144346917 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 049447 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Southeast Permanente Medical Group | 6204829013 | 576 |
News Archive
In the second year of a Northern California-based survey conducted by Sutter Health on women and heart disease, results show that more women are aware of heart attack warning signs and the need to take action quickly.
While the debate over childhood obesity rumbles on and experts search for reasons for the epidemic, a clutch of new studies recently published suggests the causes are a combination of factors.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.
› Verified 5 days ago
| Entity Name | The Southeast Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245266956 PECOS PAC ID: 6204829013 Enrollment ID: O20040407000370 |
News Archive
In the second year of a Northern California-based survey conducted by Sutter Health on women and heart disease, results show that more women are aware of heart attack warning signs and the need to take action quickly.
While the debate over childhood obesity rumbles on and experts search for reasons for the epidemic, a clutch of new studies recently published suggests the causes are a combination of factors.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Demetria M Francis, MD 3495 Piedmont Rd Ne, Nine Piedmont Center, Atlanta, GA 30305-1717 Ph: (404) 364-7070 | Dr Demetria M Francis, MD 3650 Steve Reynolds Blvd, Kaiser Permanente Gwinnett Medical Center, Duluth, GA 30096-4506 Ph: (770) 931-6220 |
News Archive
In the second year of a Northern California-based survey conducted by Sutter Health on women and heart disease, results show that more women are aware of heart attack warning signs and the need to take action quickly.
While the debate over childhood obesity rumbles on and experts search for reasons for the epidemic, a clutch of new studies recently published suggests the causes are a combination of factors.
FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.
A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.
› Verified 5 days ago
James Andrew Palmier, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 5805 State Bridge Rd, Suite G 367, Duluth, GA 30097 Phone: 678-473-0063 Fax: 678-473-0064 | |
Heidi L Chichester, P.T. Preventive Medicine Medicare: May Accept Medicare Assignments Practice Location: 2590 Peachtree Industrial Blvd, Suite D, Duluth, GA 30097 Phone: 678-667-3893 Fax: 678-303-9388 |